Developer docs
API playgroundTry for free, no card

Search company profiles

Aopia Biosciences

Full company profile

uuid000dj4k

Namestring
Aopia Biosciences
Legal namestring
Aopia Biosciences, Inc.
Websiteurl
aopiabio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Aopia Biosciences, Inc. is a privately-held biotechnology company founded in 2019 and headquartered in Pleasanton, California, that develops and commercializes tools for extracellular vesicle (EV) isolation, purification, and analysis. The company's core technology is the proprietary VanoFlow® filtration cassette, which underpins the NanoEX™ automated bio-nanoparticle isolation platform — a system that the company reports achieves greater than 99.9% free protein removal and greater than 80% EV recovery while processing 5 mL to 2 L of input material in hours with under five minutes of hands-on time. The platform is sold as a series of cassettes (EXO-01 through EXO-60) in both reusable and single-use formats, and is complemented by MSCPure™, a reagent that improves EV purity from mesenchymal stem cell cultures.

Aopia sells its instruments, consumables, and reagents directly to academic and government EV researchers (its primary segment) and to biotechnology and pharmaceutical companies working on EV-based therapeutics, biomarkers, and cell therapy manufacturing QC (its secondary segment). Distribution is augmented by an international distributor network, and the company has built visibility through the ISEV conference community and the 2023 MedTech BioTools Innovator Capstone event. Pricing is not publicly disclosed and customers engage through direct sales inquiry.

Beyond products, Aopia offers research services including NanoEX-based isolation, tangential flow filtration, size exclusion chromatography, nanoparticle tracking analysis, fluorescent EV characterization, biomarker analysis, and cell culture services spanning more than 200 cell lines at scales up to 10 L. Revenue, funding, and customer counts are not publicly disclosed, and the company appears to be at an early commercialization stage with a headcount in the 1-10 range, led by CEO Nan Su. The economic model combines instrument placement with recurring consumable and reagent revenue and a services line, targeting the workflow needs of academic core facilities and translational biotech programs.

Short descriptiontext

Aopia Biosciences is a Pleasanton, California-based biotechnology company that develops the NanoEX™ automated platform and proprietary VanoFlow® filtration cassettes for high-purity extracellular vesicle isolation, selling instruments, consumables, and research services to academic researchers and biotech/pharma customers in the EV therapeutics and diagnostics field.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPleasanton, United States
HQ citystring
Pleasanton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
extracellular vesicle isolation, bio-nanoparticle purification, exosome research instruments, filtration cassette technology, laboratory automation platforms
Industry3 codes
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAD
Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Life Science Research Instruments
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Research Instruments and Consumables
TypeHardware Sales
Description

Sale of NanoEX automated isolation platforms and VanoFlow filtration cassettes. The VanoFlow cassettes come in reusable and single-use variants, providing recurring consumable revenue opportunities.

aopiabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1NanoEX™
Description

Automated bio-nanoparticle isolation platform for EV isolation with VanoFlow® technology. Features include fully automated processing, >80% recovery rate, and >99.9% free protein removal.

aopiabio.com
+2 more records
Core offering1 text field

Aopia Biosciences develops and sells the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassette technology to isolate and purify extracellular vesicles (EVs). The company also offers MSCPure™ reagent for MSC-derived EV purity improvement and provides research services covering EV isolation, EV analysis, and cell culture for biomedical research, diagnostics, and therapeutic applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • >99.9% free protein removal
+4 more records
Product overview1 text field

Aopia Biosciences offers a portfolio of products and services for extracellular vesicle (EV) isolation and analysis. The core product is the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassettes to achieve >99.9% free protein removal. This platform is complemented by MSCPure™, a reagent that improves EV purity from MSC (mesenchymal stem cell) cultures. The company also provides research services including EV isolation (NanoEX, TFF, SEC), EV analysis (NTA, fluorescent characterization, biomarker analysis), and cell services (200+ cell lines, culture up to 10L scale, large-scale EV production).

Product and service6 records
1NanoEX™ Automated Bio-nanoparticle Isolation Platform
CategoryLife Science Research Instruments
Description

Automated bio-nanoparticle isolation instrument that provides fully automated processing with >80% EV recovery, >99.9% free protein removal, and the ability to process up to 2L of materials in hours with less than 5 minutes hands-on time; for academic researchers, biotech, and pharma customers conducting EV and exosome research.

2VanoFlow® EV Isolation Cassettes
CategoryConsumables and Reagents
Description

Filtration cassettes (VanoFlow-EXO-01, EXO-10, EXO-20, EXO-40, EXO-60) used with the NanoEX platform for EV isolation, featuring fully enclosed processing, external pressure sensing, no cleaning requirement, and elimination of cross-contamination; available in reusable and single-use variants for processing volumes from 10mL to 2L.

3MSCPure™ Reagent
CategoryConsumables and Reagents
Description

Reagent solution that improves MSC-derived EV purity by preventing protein aggregation and facilitating removal of large protein complexes from mesenchymal stem cell (MSC) conditioned culture media; for researchers working with MSC-derived EVs.

4EV Isolation Services
CategoryResearch Services
Description

Research services using NanoEX-based isolation, Tangential Flow Filtration (TFF), and Size Exclusion Chromatography (SEC) to isolate extracellular vesicles on behalf of academic and biotech customers.

5EV Analysis Services
CategoryResearch Services
Description

Analysis services including Nanoparticle Tracking Analysis (NTA), fluorescent EV characterization, and biomarker analysis for extracellular vesicle characterization.

6Cell Services
CategoryResearch Services
Description

Cell culture services offering access to over 200 cancer and normal cell lines, cell culture up to 10L scale, over-expression services, and large-scale EV production from cell lines.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1International Society for Extracellular Vesicles (ISEV)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aopia Biosciences has a strong relationship with ISEV, launching their NanoEX product at the 2024 ISEV conference and presenting at the ISEVxTech Summit. This partnership provides access to the key opinion leaders and researchers in the EV field.

aopiabio.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Supplies mesenchymal stem cell (MSC) working cell banks and MSC-derived EV products. Closely comparable to Aopia in the MSC-derived EV space, where Aopia's MSCPure reagent addresses similar MSC EV purity pain points.

TypeBroad incumbent
Description

Offers EV-related research reagents, including the ExoCap and ExoQuick product lines for exosome isolation and analysis. Overlaps with Aopia's MSCPure reagent and EV analysis services within a broader reagents and proteomics portfolio.

TypeBroad incumbent
Description

Global CDMO with growing exosome/EV manufacturing capabilities, including cell-culture and purification services for therapeutic-grade EVs. Comparable to Aopia's cell and EV production services offering, but at commercial manufacturing scale.

TypeEmerging player
Description

Developer of engineered extracellular vesicle therapeutics. Comparable to Aopia in targeting the EV therapeutics opportunity, but operating as a therapeutic developer rather than a tool provider; signals the demand profile Aopia is positioning to serve.

TypeBroad incumbent
Description

Global life-science tools leader offering EV isolation kits, ultracentrifugation equipment, and tangential flow filtration systems. Competes with Aopia's NanoEX platform across the academic and pharma EV research workflow as part of a much broader product portfolio.

6System Biosciences (SBI)
TypeDirect peer
Description

Specialist in exosome research tools, including ExoQuick precipitation kits and engineered EV products. Direct competitor in the EV isolation reagent and workflow category that Aopia's MSCPure and NanoEX target.

TypeBroad incumbent
Description

Provides exosome/EV isolation kits (e.g., exoRNeasy) and downstream nucleic acid analysis solutions. Competes with Aopia across the EV isolation workflow, with stronger downstream molecular biology attach.

TypeDirect peer
Description

Provides magnetic-bead-based EV isolation kits and instrumentation for cell and EV separation. Closely comparable to Aopia in selling automated, higher-purity EV isolation workflows to academic and translational research customers.

TypeDirect peer
Description

Specialized in exosome/EV-based liquid biopsy diagnostics and isolation technologies. Direct peer in EV isolation product development, with a focus on clinical diagnostic applications versus Aopia's research and process-development emphasis.

TypeBroad incumbent
Description

Major manufacturer of ultracentrifuges and rotors widely used for EV isolation. Represents the incumbent method that NanoEX positions against, with a deep installed base in academic and biopharma research labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aopia Biosciences

Life Science Research Instrumentsaopiabio.com

Aopia Biosciences is a Pleasanton, California-based biotechnology company that develops the NanoEX™ automated platform and proprietary VanoFlow® filtration cassettes for high-purity extracellular vesicle isolation, selling instruments, consumables, and research services to academic researchers and biotech/pharma customers in the EV therapeutics and diagnostics field.

What Aopia Biosciences does

Aopia Biosciences, Inc. is a privately-held biotechnology company founded in 2019 and headquartered in Pleasanton, California, that develops and commercializes tools for extracellular vesicle (EV) isolation, purification, and analysis. The company's core technology is the proprietary VanoFlow® filtration cassette, which underpins the NanoEX™ automated bio-nanoparticle isolation platform — a system that the company reports achieves greater than 99.9% free protein removal and greater than 80% EV recovery while processing 5 mL to 2 L of input material in hours with under five minutes of hands-on time. The platform is sold as a series of cassettes (EXO-01 through EXO-60) in both reusable and single-use formats, and is complemented by MSCPure™, a reagent that improves EV purity from mesenchymal stem cell cultures.

Aopia sells its instruments, consumables, and reagents directly to academic and government EV researchers (its primary segment) and to biotechnology and pharmaceutical companies working on EV-based therapeutics, biomarkers, and cell therapy manufacturing QC (its secondary segment). Distribution is augmented by an international distributor network, and the company has built visibility through the ISEV conference community and the 2023 MedTech BioTools Innovator Capstone event. Pricing is not publicly disclosed and customers engage through direct sales inquiry.

Beyond products, Aopia offers research services including NanoEX-based isolation, tangential flow filtration, size exclusion chromatography, nanoparticle tracking analysis, fluorescent EV characterization, biomarker analysis, and cell culture services spanning more than 200 cell lines at scales up to 10 L. Revenue, funding, and customer counts are not publicly disclosed, and the company appears to be at an early commercialization stage with a headcount in the 1-10 range, led by CEO Nan Su. The economic model combines instrument placement with recurring consumable and reagent revenue and a services line, targeting the workflow needs of academic core facilities and translational biotech programs.

Aopia Biosciences firmographics

Firmographics
Name
Aopia Biosciences
Legal name
Aopia Biosciences, Inc.
Website
https://aopiabio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Aopia Biosciences is a Pleasanton, California-based biotechnology company that develops the NanoEX™ automated platform and proprietary VanoFlow® filtration cassettes for high-purity extracellular vesicle isolation, selling instruments, consumables, and research services to academic researchers and biotech/pharma customers in the EV therapeutics and diagnostics field.
Ownership category
akta.pro rank

Aopia Biosciences industry classification

Industry
Product category
Life Science Research Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAJAD
Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Extracellular vesicle isolation
  • Bio-nanoparticle purification
  • Exosome research instruments
  • Filtration cassette technology
  • Laboratory automation platforms

Where Aopia Biosciences is headquartered

Location

Headquarters

HQ city
Pleasanton
HQ country
United States
HQ region
North America

Markets served

Aopia Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Research Instruments and Consumables: Sale of NanoEX automated isolation platforms and VanoFlow filtration cassettes. The VanoFlow cassettes come in reusable and single-use variants, providing recurring consumable revenue opportunities.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Aopia Biosciences product offering

Product offering

Core offering

Aopia Biosciences develops and sells the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassette technology to isolate and purify extracellular vesicles (EVs). The company also offers MSCPure™ reagent for MSC-derived EV purity improvement and provides research services covering EV isolation, EV analysis, and cell culture for biomedical research, diagnostics, and therapeutic applications.

Product overview

Aopia Biosciences offers a portfolio of products and services for extracellular vesicle (EV) isolation and analysis. The core product is the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassettes to achieve >99.9% free protein removal. This platform is complemented by MSCPure™, a reagent that improves EV purity from MSC (mesenchymal stem cell) cultures. The company also provides research services including EV isolation (NanoEX, TFF, SEC), EV analysis (NTA, fluorescent characterization, biomarker analysis), and cell services (200+ cell lines, culture up to 10L scale, large-scale EV production).

Differentiator

Problem solved

Functional benefit

Brands

  • NanoEX™: Automated bio-nanoparticle isolation platform for EV isolation with VanoFlow® technology. Features include fully automated processing, >80% recovery rate, and >99.9% free protein removal.
  • MSCPure™
  • VanoFlow®

Products and services

  • NanoEX™ Automated Bio-nanoparticle Isolation Platform Automated bio-nanoparticle isolation instrument that provides fully automated processing with >80% EV recovery, >99.9% free protein removal, and the ability to process up to 2L of materials in hours with less than 5 minutes hands-on time; for academic researchers, biotech, and pharma customers conducting EV and exosome research.
  • VanoFlow® EV Isolation Cassettes Filtration cassettes (VanoFlow-EXO-01, EXO-10, EXO-20, EXO-40, EXO-60) used with the NanoEX platform for EV isolation, featuring fully enclosed processing, external pressure sensing, no cleaning requirement, and elimination of cross-contamination; available in reusable and single-use variants for processing volumes from 10mL to 2L.
  • MSCPure™ Reagent Reagent solution that improves MSC-derived EV purity by preventing protein aggregation and facilitating removal of large protein complexes from mesenchymal stem cell (MSC) conditioned culture media; for researchers working with MSC-derived EVs.
  • EV Isolation Services Research services using NanoEX-based isolation, Tangential Flow Filtration (TFF), and Size Exclusion Chromatography (SEC) to isolate extracellular vesicles on behalf of academic and biotech customers.
  • EV Analysis Services Analysis services including Nanoparticle Tracking Analysis (NTA), fluorescent EV characterization, and biomarker analysis for extracellular vesicle characterization.
  • Cell Services Cell culture services offering access to over 200 cancer and normal cell lines, cell culture up to 10L scale, over-expression services, and large-scale EV production from cell lines.

Quantifiable outcome

  • >99.9% free protein removal
  • +4 more outcomes

Companies that use Aopia Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Aopia Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aopia Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • International Society for Extracellular Vesicles (ISEV)coreStrategic or Co-development PartnerAopia Biosciences has a strong relationship with ISEV, launching their NanoEX product at the 2024 ISEV conference and presenting at the ISEVxTech Summit. This partnership provides access to the key opinion leaders and researchers in the EV field.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Aopia Biosciences competitors and assessment

Company assessment

Direct peers

  • RoosterBio: Supplies mesenchymal stem cell (MSC) working cell banks and MSC-derived EV products. Closely comparable to Aopia in the MSC-derived EV space, where Aopia's MSCPure reagent addresses similar MSC EV purity pain points.
  • System Biosciences (SBI): Specialist in exosome research tools, including ExoQuick precipitation kits and engineered EV products. Direct competitor in the EV isolation reagent and workflow category that Aopia's MSCPure and NanoEX target.
  • Miltenyi Biotec: Provides magnetic-bead-based EV isolation kits and instrumentation for cell and EV separation. Closely comparable to Aopia in selling automated, higher-purity EV isolation workflows to academic and translational research customers.
  • Exosomics (now part of Lonza): Specialized in exosome/EV-based liquid biopsy diagnostics and isolation technologies. Direct peer in EV isolation product development, with a focus on clinical diagnostic applications versus Aopia's research and process-development emphasis.

Broad incumbents

  • Bio-Techne: Offers EV-related research reagents, including the ExoCap and ExoQuick product lines for exosome isolation and analysis. Overlaps with Aopia's MSCPure reagent and EV analysis services within a broader reagents and proteomics portfolio.
  • Lonza Group: Global CDMO with growing exosome/EV manufacturing capabilities, including cell-culture and purification services for therapeutic-grade EVs. Comparable to Aopia's cell and EV production services offering, but at commercial manufacturing scale.
  • Thermo Fisher Scientific: Global life-science tools leader offering EV isolation kits, ultracentrifugation equipment, and tangential flow filtration systems. Competes with Aopia's NanoEX platform across the academic and pharma EV research workflow as part of a much broader product portfolio.
  • QIAGEN: Provides exosome/EV isolation kits (e.g., exoRNeasy) and downstream nucleic acid analysis solutions. Competes with Aopia across the EV isolation workflow, with stronger downstream molecular biology attach.
  • Beckman Coulter Life Sciences: Major manufacturer of ultracentrifuges and rotors widely used for EV isolation. Represents the incumbent method that NanoEX positions against, with a deep installed base in academic and biopharma research labs.

Emerging players

  • EVOX Therapeutics: Developer of engineered extracellular vesicle therapeutics. Comparable to Aopia in targeting the EV therapeutics opportunity, but operating as a therapeutic developer rather than a tool provider; signals the demand profile Aopia is positioning to serve.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Aopia Biosciences social profiles

Digital presence

Aopia Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aopia Biosciences leadership team

Management profile

Number of profiles

Profiles1 record

Aopia Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aopia Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aopia Biosciences

What does Aopia Biosciences do?

Aopia Biosciences develops and sells the NanoEX™ automated bio-nanoparticle isolation platform, which uses proprietary VanoFlow® filtration cassette technology to isolate and purify extracellular vesicles (EVs). The company also offers MSCPure™ reagent for MSC-derived EV purity improvement and provides research services covering EV isolation, EV analysis, and cell culture for biomedical research, diagnostics, and therapeutic applications.

Is Aopia Biosciences a public or private company?

Aopia Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Aopia Biosciences founded?

Aopia Biosciences was founded in 2019. It employs 1 to 10 people.

Where is Aopia Biosciences based?

Aopia Biosciences is headquartered in Pleasanton, United States, in the North America region.

How does Aopia Biosciences make money?

One revenue line is on record: research Instruments and Consumables.

Who are Aopia Biosciences's main competitors?

Direct peers on record are RoosterBio, System Biosciences (SBI), Miltenyi Biotec and Exosomics (now part of Lonza). Broad incumbents are Bio-Techne, Lonza Group, Thermo Fisher Scientific, QIAGEN and Beckman Coulter Life Sciences. EVOX Therapeutics is listed as an emerging player.

Does Aopia Biosciences have an API?

No public API is recorded for Aopia Biosciences.

What industry is Aopia Biosciences in?

Aopia Biosciences's product category is Life Science Research Instruments. Its primary akta.pro industry code is HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers), with a secondary code of HLAAAJAD, Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales